<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00568139</url>
  </required_header>
  <id_info>
    <org_study_id>Wue-ACC-Mitotane</org_study_id>
    <nct_id>NCT00568139</nct_id>
  </id_info>
  <brief_title>Evaluation of Side Effects of Mitotane</brief_title>
  <official_title>Evaluierung Von Nebenwirkungen Einer Therapie Mit Mitotane Beim Nebennierenkarzinom- Evaluation of Side Effects of Mitotane in Adrenocortical Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Wuerzburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Wuerzburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Mitotane is standard therapy in the treatment of adrenocortical carcinoma. However, many side&#xD;
      effects are not well documented. Therefore, we are aiming at collecting data about side&#xD;
      effects in patients treated with mitotane&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 2008</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Documentation of adverse effects</measure>
    <time_frame>from starting mitotane treatment until discontinuation of mitotane (since this is very variable from patient to patient no specific number of days or weeks can be entered (standard therapy would be about 2 years)</time_frame>
    <description>Adverse effects will be documented using the NCI CTC AE v5</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Adrenocortical Carcinoma</condition>
  <arm_group>
    <arm_group_label>Mitotane</arm_group_label>
    <description>Patients with adrenocortical carcinoma treated with mitotane</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <description>Patients with adrenocortical carcinoma not treated with mitotane</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Serum, plasma, and urine samples will be collected.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with adrenocortical carcinoma treated in our center&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Adrenocortical carcinoma&#xD;
&#xD;
          -  Treatment with mitotane intended or mitotane administered&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Martin Fassnacht, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Wuerzburg</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Martin Fassnacht, MD</last_name>
    <phone>+49-931-201-36507</phone>
    <email>fassnacht_m@medizin.uni-wuerzburg.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Stefanie Hahner, MD</last_name>
    <phone>+49-931-201-36508</phone>
    <email>hahner_s@medizin.uni-wuerzburg.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Wuerzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>December 4, 2007</study_first_submitted>
  <study_first_submitted_qc>December 4, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 5, 2007</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 13, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Wuerzburg</investigator_affiliation>
    <investigator_full_name>Martin Fassnacht</investigator_full_name>
    <investigator_title>Head of Endocrinology</investigator_title>
  </responsible_party>
  <keyword>adrenal cancer</keyword>
  <keyword>mitotane (Lysodren)</keyword>
  <keyword>adverse events</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Adrenocortical Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

